Humira

Credit Suisse Says AbbVie’s Humira Patent Cliff Could Provide Momentum to Boost Growth

by

Credit Suisse has initiated coverage on AbbVie Inc (NYSE: ABBV) with an Outperform rating and a price target of $170. AbbVie stands on the edge of best-selling Humira’s U.S. loss of exclusivity (LOE) in 2023. While this remains the focus of investor discussions, Credit Suisse sees it as a catalyst to push the narrative from a value story to … Read more

AbbVie Stock: Is ABBV Stock A Buy Or A Sell With Humira Rivals Looming?

by

AbbVie stock tumbled in late July after the company posted a mixed second-quarter report that relied heavily on its immunology drugs to make up for other shortfalls. X While all three immunology treatments beat expectations, AbbVie‘s (ABBV) sales of the company’s blood cancer treatments and its overall aesthetics franchise came in light. One analyst said … Read more